When a Drug Launch Moves, the Business Changes Too
What Roche's European plans mean for pharmaceutical companies and investors
By Ron Lanton
For pharmaceutical companies, getting a new drug approved is only part of the job. Deciding when and where to introduce it can be just as important.
Those decisions are becoming more complicated as the United States pushes drugmakers to narrow the difference between American and foreign drug prices.
In an October 26 Endpoints News article, Maggie Fick reported that Roche has changed its anticipated European regulatory timeline for giredestrant, an investigational breast cancer treatment.
Roche previously expected to seek European approval in 2026. It now plans to begin discussions with European regulators in 2027, without providing a new filing date.
Roche says it wants more mature clinical evidence to support its application and improve its prospects for sustainable reimbursement. There is no public evidence establishing that U.S. most-favored-nation (MFN) pricing policy caused the change.
Still, the development raises a question worth examining.
Why launch timing matters
Drugmakers have traditionally introduced new medicines in the United States first, where the commercial opportunities have generally been greater.
Europe presents a different calculation. Companies must consider regulatory requirements, health technology assessments and pricing negotiations that vary across countries.
Germany's AMNOG system and France's pharmaceutical pricing framework are examples of those differences.
Now add the possibility that lower prices negotiated overseas could influence what a company receives in the United States.
That could change how executives evaluate the timing of European launches.
For patients, the consequences can be substantial. A delayed launch may mean waiting longer for access to a treatment.
The financial implications
For biotechnology companies, regulatory approval and commercial access are not the same thing.
A company may receive approval but still face months of reimbursement negotiations and additional evidence requirements before reaching a broad patient population.
These decisions affect revenue forecasts, manufacturing, distribution agreements and financing needs.
They can also influence licensing and acquisition negotiations. Investors and potential buyers need to understand not only whether a product is likely to receive approval, but when it can begin generating revenue in different markets.
A delayed filing does not necessarily translate into an equivalent delay in sales. Each market has its own regulatory and reimbursement timelines.
What executives should be watching
According to the Endpoints News analysis, 44 new medicines entered European regulatory review during the first nine months of 2026, compared with 51 during the same period in 2025.
That decline deserves attention, but it does not establish that U.S. pricing policy caused it. Europe faced challenges attracting innovative medicines before MFN entered the discussion.
The concern is that MFN could make an already complicated situation more difficult.
For pharmaceutical executives, regulatory planning, pricing and reimbursement need to be considered together.
For investors, the questions extend beyond FDA approval dates. International launch schedules, reimbursement assumptions and the timing of expected revenue all deserve attention.
A promising medicine is only part of the investment case. Getting it to patients, and understanding when that can happen, matters just as much.
Ron Lanton is Senior Partner and Global Strategist at Lanton, Lanton & Sosa Law PLLC.
Related reporting: Maggie Fick, “Roche's changing plans show how MFN is complicating European drug launches,” Endpoints News, October 26, 2026.